Neurocrine Biosciences, Inc.
George J Morrow (Director) sells NBIX shares
About this filing
Neurocrine Biosciences, Inc. (NBIX) filed Form 4 (insider transaction) with the SEC on Nov 3, 2026. Form 4 reports a company insider’s trades in the company’s shares.
Key facts
- Insider
- George J Morrow · Director
Rule 10b5-1 plan · adopted May 26, 2026
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Oct 30, 2026 | M · exercise or conversion of a derivative | +300 | $53.64 | $16,092.00 | 10,686 | Direct |
| Oct 30, 2026 | S · open-market saleFootnotes F1 | −300 | $149.00 | $44,700.00 | 10,386 | Direct |
| Nov 2, 2026 | M · exercise or conversion of a derivative | +7,500 | $53.64 | $402,300.00 | 17,886 | Direct |
| Nov 2, 2026 | S · open-market saleFootnotes F1, F2 | −1,900 | $144.98 | $275,452.69 | 15,986 | Direct |
| Nov 2, 2026 | S · open-market saleFootnotes F1, F3 | −4,300 | $145.86 | $627,194.13 | 11,686 | Direct |
| Nov 2, 2026 | S · open-market saleFootnotes F1, F4 | −1,300 | $146.76 | $190,783.06 | 10,386 | Direct |
| Nov 3, 2026 | M · exercise or conversion of a derivative | +7,200 | $53.64 | $386,208.00 | 17,586 | Direct |
| Nov 3, 2026 | S · open-market saleFootnotes F1 | −100 | $158.18 | $15,818.00 | 17,486 | Direct |
| Nov 3, 2026 | S · open-market saleFootnotes F1 | −100 | $162.05 | $16,205.00 | 17,386 | Direct |
| Nov 3, 2026 | S · open-market saleFootnotes F1, F5 | −600 | $163.71 | $98,224.98 | 16,786 | Direct |
| Nov 3, 2026 | S · open-market saleFootnotes F1, F6 | −1,226 | $164.74 | $201,971.49 | 15,560 | Direct |
| Nov 3, 2026 | S · open-market saleFootnotes F1, F7 | −908 | $165.71 | $150,461.05 | 14,652 | Direct |
| Nov 3, 2026 | S · open-market saleFootnotes F1, F8 | −1,466 | $166.77 | $244,491.86 | 13,186 | Direct |
| Nov 3, 2026 | S · open-market saleFootnotes F1, F9 | −1,500 | $167.72 | $251,587.20 | 11,686 | Direct |
| Nov 3, 2026 | S · open-market saleFootnotes F1, F10 | −1,300 | $168.53 | $219,092.25 | 10,386 | Direct |
| Oct 30, 2026 | M · exercise or conversion of a derivativeNon-Qualified Stock OptionFootnotes F11 | −300 | $0.00 | $0.00 | 14,700 | Direct |
| Nov 2, 2026 | M · exercise or conversion of a derivativeNon-Qualified Stock OptionFootnotes F11 | −7,500 | $0.00 | $0.00 | 7,200 | Direct |
| Nov 3, 2026 | M · exercise or conversion of a derivativeNon-Qualified Stock OptionFootnotes F11 | −7,200 | $0.00 | $0.00 | 0 | Direct |
Footnotes
- F1 The dispositions reported in this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- F2 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $144.32 to $145.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $145.35 to $146.34. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F4 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $146.38 to $147.26. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F5 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $163.21 to $164.01. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F6 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $164.22 to $165.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F7 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $165.26 to $166.24. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F8 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $166.26 to $167.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F9 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $167.27 to $168.18. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F10 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $168.27 to $169.10. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F11 The option was granted May 22, 2017 and vested in 12 equal monthly installments beginning June 22, 2017. These options were scheduled to expire on May 22, 2027.
More NBIX filings
- 4
Filed Nov 19, 2026
- 144
Filed Nov 17, 2026
- 144
Filed Nov 10, 2026
- 4
Filed Nov 5, 2026
- 4
Filed Nov 3, 2026
- 144
Filed Nov 2, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.